Michel Roy
Net worth: - $ as of 2026-05-30
Net worth: - $ as of 2026-05-30
Michel Roy is currently Chief Commercial Officer at Sunshine Biopharma, Inc. since 2025.
Formerly, Mr. Roy was Vice President-Business Development & Sales at Intas Pharmaceuticals Ltd. from 2014 to 2020.
Education includes an MBA from John Molson School of Business in 2010, an undergraduate degree from Concordia University in 1990, and a graduate degree from the University of Montréal in 1999.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-02-17 | 0 ( -.--% ) | - $ | 2026-05-30 |
| Companies | Position | Start |
|---|---|---|
| SUNSHINE BIOPHARMA, INC. | Corporate Officer/Principal | 2025-01-14 |
| Companies | Position | End |
|---|---|---|
Intas Pharmaceuticals Ltd.
Intas Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Operates as a vertically integrated pharmaceutical formulation development, manufacturing and marketing company | Sales & Marketing | 2020-05-31 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 5 |
|---|---|
Concordia University
Concordia University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Montréal
University of Montréal Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Intas Pharmaceuticals Ltd.
Intas Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Operates as a vertically integrated pharmaceutical formulation development, manufacturing and marketing company | Health Technology |
Sunshine Biopharma, Inc.
Sunshine Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes drugs for the treatment of cancer | Health Technology |
John Molson School of Business
John Molson School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Select your edition
All financial news and data tailored to specific country editions